Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a Phase III trial in ovarian cancer.
In the ROSELLA study (NCT05257408), which enrolled 381 patients with platinum-resistant ovarian cancer, patients treated with relacorilant plus nab-paclitaxel experienced a 35% reduction in the risk of death compared to patients treated with nab-paclitaxel alone. The median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone, a difference of 4.1 months.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Dr Alexander Olawaiye, director of gynaecological cancer research at Magee-Women’s Hospital of the University of Pittsburgh and principal investigator in the trial, said: “The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, due to its overall survival benefit, well-tolerated side effect profile and oral administration. Importantly, the Phase III trial results are not limited to patients with any particular biomarker requirement.”
The company’s stock rose 14.6% after the endpoint success was announced, from $36.31 at market close on 21 January to $41.62 at market open on 22 January. The company has a market cap of $4.36bn.
In April 2025, Corcept announced that ROSELLA met its primary endpoint of improved progression-free survival (PFS), with a 30% reduction in the risk of disease progression between the two cohorts.
Relacorilant in combination with nab-paclitaxel was well-tolerated, consistent with its known safety profile. The frequency and severity of adverse events (AEs) in the combination arm were comparable to those in the nab-paclitaxel monotherapy arm.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataComplete results from ROSELLA will be presented at an upcoming medical conference.
Corcept is currently studying relacorilant, which is taken orally, in other solid tumours, including platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancers.
The company suffered a stock hit at the end of December 2025 after receiving a complete response letter (CRL) from the US Food and Drug Agency (FDA) for relacorilant in Cushing’s syndrome.
While the agency agreed that both the GRACE and GRADIENT trials supported the filing, the agency required additional evidence of effectiveness to balance out the benefit-risk ratio.
